First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

被引：0

作者：

Yanli Zhuang

Cesar Calderon

Stanley J Marciniak

Esther Bouman-Thio

Philippe Szapary

Tong-Yuan Yang

Allen Schantz

Hugh M. Davis

Honghui Zhou

Zhenhua Xu

机构：

[1] Janssen Research & Development,Biologics Clinical Pharmacology

[2] LLC,Compound Development

[3] Janssen Research & Development,Clinical Research

[4] LLC,Immunology

[5] DePuy Orthopaedics US Inc.,Quantitative Sciences

[6] Janssen Research & Development,undefined

[7] LLC,undefined

[8] Janssen Research & Development,undefined

[9] LLC,undefined

来源：

European Journal of Clinical Pharmacology | 2016年 / 72卷

关键词：

Anti-interleukin-23; Monoclonal antibody; Guselkumab; First-in-human; Pharmacokinetics; Safety;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1303 / 1310

页数：7

共 50 条

[31] Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1 Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis
Yao, Zhenling
Hu, Chuanpu
Zhu, Yaowei
Xu, Zhenhua
Randazzo, Bruce
Wasfi, Yasmine
Chen, Yang
Sharma, Amarnath
Zhou, Honghui
JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (05): : 613 - 627
[32] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Tadao Akizawa
Ryutaro Shimazaki
Masanari Shiramoto
Masafumi Fukagawa
Clinical Drug Investigation, 2018, 38 : 945 - 954
[33] A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects
Ahmadi, Ali R.
Atiee, George
Chapman, Bart
Reynolds, Laurie
Sun, John
Cameron, Andrew M.
Wesson, Russell N.
Burdick, James F.
Sun, Zhaoli
CELL REPORTS MEDICINE, 2023, 4 (09)
[34] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Akizawa, Tadao
Shimazaki, Ryutaro
Shiramoto, Masanari
Fukagawa, Masafumi
CLINICAL DRUG INVESTIGATION, 2018, 38 (10) : 945 - 954
[35] Safety in patients with latent tuberculosis (TB) treated with guselkumab and anti-TB treatments in the phase 3 VOYAGE 1 and 2 trials for moderate-to-severe plaque psoriasis
Puig, L.
Tsai, T. -F.
Bhutani, T.
Uy, J.
Ramachandran, P.
Song, M.
You, Y.
Gooderham, M.
Lebwohl, M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 41 - 42
[36] Results of a single ascending dose study to assess the safety and tolerability of CNTO 1959 following intravenous or subcutaneous administration in healthy subjects and in subjects with moderate to severe psoriasis
Sofen, H.
Smith, S.
Matheson, R.
Leonardi, C.
Calderon, C.
Bouman-Thio, E.
Brodmerkel, C.
Li, K.
Marciniak, S.
Petty, K.
Wasfi, Y.
Wang, Y.
Szapary, P.
Krueger, J.
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E10 - E10
[37] Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Nuggehally R. Srinivas
Clinical Drug Investigation, 2019, 39 : 105 - 107
[38] Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Srinivas, Nuggehally R.
CLINICAL DRUG INVESTIGATION, 2019, 39 (01) : 105 - 107
[39] A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers
Sjoberg, Folke
Waters, Susanna
Lofberg, Boel
Sonesson, Clas
Waters, Nicholas
Tedroff, Joakim
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (03):
[40] First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults
Mammen, Mammen P.
Armas, Danielle
Hughes, Frank H.
Hopkins, Andrew M.
Fisher, Cindy L.
Resch, Pamela A.
Rusalov, Denis
Sullivan, Sean M.
Smith, Larry R.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (11)

← 1 2 3 4 5 →